New Zealand Formulary
Fewer cancers.
Better survival.
Equity for all.
+Apply search filters
Filters (click item to remove)
Select Filter
Cancer type
Treatment setting
Subtype
Select option
Breast
Central Nervous System
Colorectal
Desmoid fibromatosis
Giant Cell tumour of bone
Gynaecological
Haematopoietic Stem cell transplant
Head and Neck
Leukaemias
Lymphoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Neuroendocrine carcinoma
Neuroendocrine neoplasm
Neuroendocrine tumour
Plasma cell neoplasm
Respiratory
Sarcoma
Skin Cancer
Upper gastrointestinal
Urogenital
Select Setting
Adjuvant
Advanced
Definitive
Extensive
Limited
Locally advanced
Metastatic
Neoadjuvant
NON-Metastatic
Recurrent
Refractory
Relapsed
Select Subtype
Acute lymphoblastic
Acute Lymphoblastic B-cell leukaemia/lymphoma
Acute Lymphoblastic T-cell leukaemia/lymphoma
Acute myeloid
Acute promyelocytic with PML-RARA
Anal
Basal Cell
Biliary
Bladder
Bladder Urothelial
Cervical
Chronic lymphocytic
Chronic myeloid
Chronic myelomonocytic
Endometrial
Gallbladder
Gastric
Gastrointestinal stromal cell tumours
Gestational trophoblastic disease
Glioblastoma
Glioma
Hairy cell
Hepatic
Hodgkin
Mantle cell lymphoma
Melanoma
Merkel Cell
Mesothelioma
Multiple myeloma
Myelodysplastic disorders
Myelodysplastic syndrome unclassifiable
Myelofibrosis
Nasopharyngeal
Neuroendocrine
Neuroendocrine
Non small cell lung cancer
non-Hodgkin
Non-Hodgkin B-Cell
Non-Hodgkin T-cell
Oesophageal
Ovarian
Pancreas
Penile
Primary CNS lymphoma
Prostate
Rectal
Renal cell
Salivary gland
Small cell lung cancer
Soft tissue sarcoma
Squamous Cell
T-cell prolymphocytic
Testicular germ cell
Thyroid
Upper Tract Urothelial
Urothelial
Vulval
Cancer Type
—
Breast
Central Nervous System
Colorectal
Gynaecological
Haematopoietic Stem Cell Transplant
Head and Neck
Leukaemias
Lymphoma
Neuroendocrine
Plasma Cell Neoplasms
Respiratory
Sarcoma
Skin Cancer
Upper Gastrointestinal
Urogenital
Request a new regimen
Terms of Use, Guidance and Disclaimers
What's new
Subscribe to monthly updates
Resources
Systemic Anti-Cancer Therapy Regimen Library
Home
>
Haematopoietic Stem Cell Transplant
Haematopoietic Stem Cell Transplant Regimens
Published
Name
Version
Date
HSCT Allogeneic conditioning Myeloablative Haploidentical - Flu/Bu4 with PTCy [fludarabine and busulfan with post-transplant CYCLOPHOSPHamide]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Myeloablative Matched unrelated donor - Bu/Cy/ATG [busulfan, CYCLOPHOSPHamide and Thymoglobuline]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Myeloablative Matched unrelated donor - Flu/Bu4/ATG [fludarabine, busulfan, and Thymoglobuline]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Myeloablative Sibling - Bu/Cy [busulfan and CYCLOPHOSPHamide]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Myeloablative Sibling - Flu/Bu4 [fludarabine and busulfan]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Reduced intensity Matched unrelated donor - Flu/Bu2/ATG [fludarabine, busulfan, and Thymoglobuline]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Reduced intensity Sibling - Flu/Bu2 [fludarabine and busulfan]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Reduced intensity Sibling - Flu/Bu3 [fludarabine and busulfan]
1.0.0
28/11/2024
HSCT Allogeneic conditioning Reduced intensity Sibling - Flu/Mel [fludarabine and melphalan]
1.0.0
28/11/2024
HSCT Autologous conditioning - BEAM [carmustine, etoposide, cytarabine and melphalan] [lymphoma]
1.0.0
28/11/2024
HSCT Autologous conditioning - carmustine and thiotepa [CNS lymphoma]
1.0.0
28/11/2024
HSCT Autologous conditioning - CBV [CYCLOPHOSPHamide, carmustine and etoposide] [lymphoma]
1.0.0
28/11/2024
HSCT Autologous conditioning - melphalan 140
1.0.0
28/11/2024
HSCT Autologous conditioning - melphalan 200
1.0.0
28/11/2024
HSCT Mobilisation - CYCLOPHOSPHamide and filgrastim
1.0.0
28/11/2024
HSCT Mobilisation - filgrastim
1.0.0
28/11/2024
HSCT Mobilisation - filgrastim and plerixafor
1.0.0
28/11/2024